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Abstract The detection and quantification of coronary ar-
tery calcification (CAC) significantly improves cardiovas-
cular risk prediction in asymptomatic patients. Many have
advocated for expanded CAC testing in symptomatic pa-
tients based on data demonstrating that the absence of quan-
tifiable CAC in patients with possible angina makes
obstructive coronary artery disease (CAD) and subsequent
adverse events highly unlikely. However, the widespread
use of CAC testing in symptomatic patients may be limited
by the high background prevalence of CAC and its low
specificity for obstructive CAD, necessitating additional
testing (‘test layering’) in a large percentage of eligible
patients. Further, adequately powered prospective studies
validating the comparative effectiveness of a ‘CAC first’
approach with regards to cost, safety, accuracy and clinical
outcomes are lacking. Due to marked reductions in patient
radiation exposure and higher comparative accuracy and
prognostic value make coronary computed tomographic an-
giography the preferred CT-based test for appropriately se-
lected symptomatic patients.
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Introduction
Chest pain accounts for approximately 5–6 million emer-
gency department (ED) visits and 1 in every 50 outpatient
visits in the United States, ultimately costing more than $6
billion dollars in annual healthcare costs [1]. While a ma-
jority of presentations for chest pain are ultimately deemed
non-cardiac in origin, in light of the substantial morbidity
and mortality due to coronary heart disease, most patients
undergo non-invasive testing for coronary artery disease
(CAD) to better define individual cardiovascular risk. In
an era of increasing focus on healthcare resource utilization,
considerable interest is aimed at reducing the cost and time
to provide appropriate care, ultimately identifying the right
test, for the right patient, in the right clinical presentation
(assuming a test is needed or indicated at all). Beyond its
role as a well-established screening test for subclinical cor-
onary atherosclerosis in asymptomatic patients, coronary
artery calcium (CAC) testing has garnered increasing atten-
tion as an inexpensive, rapid, reproducible and safe alterna-
tive to exclude CAD in symptomatic patients at low-
intermediate pre-test risk for obstructive coronary athero-
sclerosis. Current National Institute for Health and Clinical
Excellence (NICE) guidelines recommend testing for CAC
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as the first-line examination in lower risk patients with
stable chest pain symptoms [2••]. However, several potential
limitations of this approach have curbed the widespread use
of CAC testing in symptomatic patients and led to discor-
dant recommendations from other professional societies.
These include concerns for the presence of obstructive dis-
ease in the absence of CAC, particularly in patients at higher
pre-test risk, the high background prevalence of CAC in the
general population, and a low-specificity of CAC for ob-
structive disease, necessitating additional testing in a signif-
icant percentage of patients with evident CAC. The concern
for diagnostic inefficiency due to test layering in symptom-
atic patients with positive CAC, as well as the ability to
perform coronary computed tomographic angiography
(CTA), with proven accuracy and prognostic value at radi-
ation doses comparable to CAC testing in many patients, are
prominent limitations to CAC testing in symptomatic pa-
tients in our practice. Herein, we review the evidence
supporting CAC testing in symptomatic patients as well as
the challenges to its widespread application.
Noninvasive Cardiac Testing – Current Approaches
and Limitations
In order to understand the rationale for utilizing CAC testing
in patients with symptoms concerning for angina, one must
consider contextually the test performance, cost and current
guideline recommendations for standard non-invasive tests
for CAD (Fig. 1). Exercise stress electrocardiography
(ECG) is commonly performed, relatively inexpensive, can
be completed with limited support staff and does not involve
ionizing radiation exposure; though it requires an interpret-
able electrocardiogram and an ambulatory patient. While
exercise capacity remains one of the strongest indicators of
long-term mortality, the diagnostic accuracy of exercise
ECG is low relative to imaging-based tests for CAD. For
example, based on pooled summary test performance statis-
tics, exercise ECG has a sensitivity of 68% and specificity
of 77% for the detection of obstructive CAD on invasive
coronary angiography [3]. For this reason, NICE guidelines
discourage the use of exercise ECG for the evaluation of
patients with stable angina symptoms in patients without
known CAD, despite European Society of Cardiology and
American College of Cardiology Foundation / American
Heart Association (ACCF/AHA) guidelines to the contrary
[2••, 4, 5••]. Indeed, exercise ECG confers the only class I
indication for the initial evaluation of suspected stable is-
chemic heart disease in intermediate risk patients with an
interpretable ECG who are able to exercise [5••].
Stress echocardiography and single-photon emission
computed tomography (SPECT) both improve diagnostic
accuracy for the detection of obstructive coronary artery
disease as compared to stress ECG at the expense of time,
Fig. 1 Comparison of commonly utilized non-invasive tests for coro-
nary artery disease in patients with suspected ischemic heart disease.
ACS, acute coronary syndrome; CAC, coronary artery calcium; CTA,
computed tomographic angiography; ECG, electrocardiogram; mSv,
millisievert; SPECT, single-photon emission computed tomography; U,
uncertain. * Per-patient sensitivity and specificity for obstructive coro-
nary artery disease defined as ≥50% coronary luminal narrowing con-
firmed by invasive coronary angiography according to mean values as
reported in current American College of Cardiology Guidelines. Sensi-
tivity for ‘CAC=0’ derived as the weighted mean from Sarwar et al. [24]
and Villines et al. [34••]. # Calendar Year 2012 final Outpatient Prospec-
tive Payment System (OPPS)applying procedure codes: Stress ECG
(93306), Stress Echo (93351), SPECT (78452), CAC (75571), CCTA
(75574), ICA (93458). Note the coverage for coronary artery calcium
scanning is limited in many regions. ¶ When follow-up 12-lead ECG and
cardiac biomarkers are unremarkable. ^ In patients able to exercise CCTA
meets Class IIa indication if patient (a) has continued symptoms with
prior normal test findings (b) has inconclusive results from prior exercise
or pharmacological stress testing, or (c) is unable to undergo stress with
myocardial perfusion imaging or echocardiography
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resource availability and cost. Of these, stress echocardiog-
raphy has greater specificity with lower cost and no radia-
tion, but ultimately relies on experienced technicians and
readers and adequate image quality to maintain accuracy
and reproducibility. While SPECT improves sensitivity for
detecting significant CAD [6, 7], it remains more expensive,
time consuming and incurs significant radiation, though
stress only imaging may limit these drawbacks while pro-
viding sufficient negative predictive value (NPV) in low-
intermediate risk patients [8].
Lastly, modern coronary CTA has proven to be the most
sensitive noninvasive modality to evaluate suspected coro-
nary artery disease in patients with stable or acute chest pain
syndromes [9, 10]. While CCTA exposes patients to ioniz-
ing radiation, very low effective doses (<5 millisieverts;
mSv) are now routinely achieved due to advances in scanner
technology and image acquisition protocols [11]. Though
CCTA requires specialized personnel and equipment that
may not be widely available, data has demonstrated the
potential for CCTA to reduce costs relative to standard of
care primarily in its ability to reduce the time to diagnose
patients in the ED setting [12]. Based on its excellent diag-
nostic accuracy, prognostic value [13, 14•, 15•], and poten-
tial to improve the early triage of ED patients, CCTA
currently is given a class IIa indication to evaluate low-
intermediate risk patients with suspected acute coronary
syndrome (ACS) in whom follow-up 12-lead ECG and
cardiac biomarkers are normal (Fig. 1) [16].
Coronary Artery Calcium Testing in Symptomatic Patients
As a non-invasive measure of overall coronary artery disease
burden [17], CAC testing is a clinically useful screening test for
coronary atherosclerosis. It is currently recommended by
ACCF/AHA guidelines in select asymptomatic patients [18•]
based on data demonstrating that it significantly improves risk
prediction as compared to current global cardiovascular risk
scores and the use of highly-sensitive C-reactive protein testing
[19, 20]. Among asymptomatic screening patients, the absence
of coronary calcification (CAC=0) using standard Agatston
CAC scoring [21] identifies patients with extremely low rates
of subsequent mortality and cardiovascular events [22–24]
among patients of diverse age groups [25]. The use of CAC
testing in symptomatic patients has traditionally been limited
due to fundamental concerns thought to limit its accuracy
and/or diagnostic efficiency that include the: (1) occurrence
of coronary calcification relatively late in the atherosclerotic
process ; (2) high prevalence of CAC in the population and the
lack of its specificity for obstructive CAD; (3) demonstration of
significant ethnic variability in plaque composition and calcifi-
cation patterns; and (4) fact that high risk coronary lesions often
demonstrate little or no calcification [26–31].
Diagnostic Accuracy of Absent Coronary Calcification
Studies regarding the diagnostic accuracy of CAC testing in
symptomatic patients have generally reported high sensitivity
and negative predictive values (NPV) for obstructive CAD in
the absence of coronary artery calcification. These values com-
pare favorably to many widely used functional tests for CAD
(Fig. 1) [24]. However, as may be expected, the presence and
severity of CAC has limited specificity and positive predictive
value for the presence of angiographically significant CAD,
generally defined as ≥50% lumen stenosis on invasive coronary
angiography (ICA). Sarwar and colleagues performed a meta-
analysis of 10,355 predominately symptomatic patients under-
going primarily electron-beam computed tomography (EBCT;
n=8751) and demonstrated excellent sensitivity (98%) and
NPV (93%) for CAC>0 when compared to blinded ICA
findings among patients with stable symptoms. Within this
cohort, overall specificity of CAC>0 was 40% and positive
predictive value (PPV) was 68% for obstructive CAD. Based
on such data, a 2007 ACC/AHA expert consensus statement
[32] and recent NICE guidelines [2••] endorsed the use of CAC
testing for low-risk, stable symptomatic patients, where CAC
testing is used as a filter for further cardiovascular testing in a
binary fashion (CAC present or absent). Specifically, patients
without CAC (CAC=0) avoid further cardiovascular testing
(CAD ruled out) and those with any CAC (CAC>0) receive
additional testing, such as CCTA, SPECTor ICA, an approach
also advocated by some expert opinion [33].
Subsequent studies utilizing multi-detector computed to-
mography (MDCT) scanners have similarly provided promis-
ing data demonstrating generally high, albeit variable,
sensitivity and negative predictive values for binary CAC test-
ing among symptomatic patients (Table 1). Recently, investi-
gators from the Coronary CT Angiography Evaluation for
Clinical Outcomes: An International Multicenter registry
(CONFIRM) evaluated 10,037 symptomatic low-intermediate
risk patients undergoing≥64 slice CCTA and found high sen-
sitivity and NPV for the detection of any stenosis ≥50% (sen-
sitivity 89%, NPV 96%) and ≥70% (sensitivity 92%, NPV
99%), respectively [34••]. Within this cohort more than 13%
of patients with CAC=0 had non-obstructive CAD (purely
non-calcified plaque), and 3.5% and 1.4% had a stenosis
≥50% and ≥70%, respectively. Notably, in both the Sarwar
analysis and CONFIRM populations, NPV remained high
(>95%) despite marked differences in the prevalence of ob-
structive disease (≥50% stenosis), 56% and 16%, respectively.
However, in reviewing other MDCT studies, the reported
sensitivity and NPVof CAC scoring in symptomatic patients
are highly variable (Table 1) [35, 36, 37•, 39–41]. Examina-
tion of these studies provides a case-study for the effect of pre-
test probability on test performance in accordance with Bayes-
ian principles. A sub-study of the Coronary Evaluation Using
Multi-Detector Spiral Computed Tomography Angiography
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Using 64 Detectors (CORE 64) multi-center trial demonstrated
that among 291 high risk symptomatic patients with suspected
ACS, 19% of those with CAC=0 had at least one segment of
≥50% stenosis on subsequent ICA [37•]. Similarly, Henneman
and colleagues cautioned against the extension of CAC in the
ED setting after reporting that among 40 patients presenting
with suspected ACS, 12.5% (n=5) had significant CAD in the
absence of calcification [39]. Importantly, these represent
smaller studies involving higher-risk patients clinically referred
for ICA, a scenario where CAC scoring would generally be
inappropriate; and neither study excluded patients with known
CAD. In the Henneman paper, for example, 25% and 28% of
patients had a prior myocardial infarction and percutaneous
coronary intervention, respectively. Here, commentary by
Blaha et al. regarding the use of Bayes theorem reminds us
that as disease prevalence (pretest probability) increases the
ability of any non-invasive test to exclude obstructive disease
(sensitivity and negative predictive value) is eroded [42].
Given the discrepancy among existing heterogeneous data
regarding the accuracy of binary CAC testing suggests that
there is a need for prospective studies assessing the clinical
outcomes, cost and safety of this approach prior to widespread
clinical adoption of early CAC testing in symptomatic pa-
tients. Noting similar sentiment, in the 2012 ACCF/AHA
guideline for the diagnosis of patients with potential stable
ischemic heart disease, binary CAC testing in symptomatic
patients was given a class IIb recommendation (level of evi-
dence ‘C’: may be considered; additional studies are needed;
divergence of opinion), with the writing committee stating that
“additional evidence in sufficiency large cohorts of patients
establishing the uncorrected diagnostic accuracy of CAC to
rule in or rule out high-grade coronary artery stenosis in
symptomatic patients [is] needed” [5••].
Prognostic Value of a Zero Calcium Score
in Symptomatic Patients
Beyond its proven prognostic value in screening populations
and its diagnostic potential in symptomatic patients to rule-out
significant CAD as discussed above, the prognostic value of
CAC testing in symptomatic patients warrants discussion. One
of the first studies to evaluate the use of CAC scoring in
symptomatic patients in the ED was performed by Georgiou
and colleagues [43]. A total of 192 low-intermediate risk
patients with suspected CAD underwent calcium scoring in
the ED. The treating physician and patient were blinded to
CAC results and subjects were followed up to 7 years. Patients
with CAC=0 had an annualized event rate of 0.6% for a
composite of cardiac death, stroke, myocardial infarction, re-
vascularization and hospitalization for angina. The sensitivity
and NPV for predicting any cardiac event were both 97%. The
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Tomography (ROMICAT I) study consisted of 368 symptom-
atic patients undergoing CCTA and CAC scans for the evalu-
ation of acute chest pain in the ED. Of the 14 patients (4%)
with purely non-calcified plaque(s), only one (7.1%) devel-
oped ACS, a NPV for binary CAC testing of 99% [44]. Finally,
from among a larger cohort study of more than 1000 patients it
was shown that 60% of low-intermediate risk symptomatic
patients referred for stress SPECT had a CAC score of zero,
prompting the authors to conclude that these patients could
have been discharged without additional evaluation [45]. Car-
diac death and ACS occurred in only two (0.3%) of the 625
CAC=0 patients over a 7 month follow-up period, providing a
sensitivity and NPVof 93.8% and 99.7%, respectively. On the
other hand, 12 (1.2%) of 991 patients with a normal SPECT
suffered an event with a sensitivity and NPV of 62.5% and
98.8% respectively (p=0.04 for sensitivity). Similar to these
findings, a number of other studies attest to the prognostic
reassurance provided by the absence of quantifiable CAC on
non-contrast CT (Table 2) [34••, 46–53].
It is important to note that when comparing the prognos-
tic value of CAC Agatston scores (plaque burden) versus
coronary CTA, which provides angiographic measures of
plaque burden, plaque composition and coronary artery
stenosis, CAC scoring does not appear to provide significant
additional prognostic information among symptomatic pa-
tients. Data from the CONFIRM registry [34••] and others
[54] have shown that CCTA provides superior prognostic
information as compared to CAC testing among symptom-
atic patients (Fig. 2). Additionally, among patients with
obstructive (≥50% stenosis) disease on CCTA but with
CAC=0 (3.5% of patients with CAC=0) within CONFIRM,
there was a significant increase in cardiovascular events
related to the presence of obstructive CAD (Fig. 3) [34••].
Within this important registry, there was no additional prog-
nostic value for CCTA as compared to CAC scoring in
asymptomatic patients [55]. Taken together, these observa-
tions appear to support current appropriate use criteria [56]
and guidelines for the use of CT-based CAD tests [4, 5••, 16,
18•], highlighting the importance of patient symptoms in
this decision-making process.
Limitations of CAC Testing in Symptomatic Patients:
A Question of Diagnostic Efficiency
Based on the data discussed above, when taken in aggregate,
CAC testing in symptomatic patients performs reasonably
well for excluding significant CAD in symptomatic patients,
based primarily on its high sensitivity and NPV. However,
widespread endorsement of this approach should be cau-
tioned for several reasons [57]. First, unlike comparable
testing options, CAC scoring is a marker of CAD burden
and not a direct anatomic or physiologic assessment of
stenosis or ischemia, respectively, the primary features that
typically guide treatment in symptomatic patients. In addition,
based on the fact that calcification occurs relatively late in the
atherosclerotic process, CAC testing in younger patients, in
whom a smaller percentage of atherosclerosis may be calci-
fied, may lead to false negative tests. For example, it has been
reported that up to 47% of patients at autopsy during their
third decade of life have identifiable coronary plaque but only
about 3% of these lesions were calcified [58]. Additionally,
symptomatic patients with absent CAC and significant CAD
are more likely to be smokers and have a family history of
premature CAD [34••]. Conversely, performance of CAC in
older symptomatic patients, a cohort with higher CAC prev-
alence, may lead to the need for additional testing as a larger
percentage of patients will have CAC>0.
Diagnostic Efficiency and Cost Considerations
Ultimately, the primary issue that should limit the use of
CAC testing in symptomatic patients is that of diagnostic
inefficiency related to the high rate of additional non-
invasive testing (test layering) required for patients with
positive CAC when a ‘CAC first’ approach is applied in
low-intermediate risk symptomatic patients. For example,
from within the CONFIRM registry, a low-intermediate risk
cohort that would generally qualify for CAC testing
according to NICE guidelines, 49% of patients had a CAC
score >0. Hence, the performance of up-front CAC scoring
would have led to approximately half of all patients requir-
ing an early secondary non-invasive test for further evalua-
tion. In practice, we suspect that subsequent testing would
generally be stress imaging tests given the limitations of
exercise ECG alone, adding to evaluation costs, time to
diagnosis and an increase in radiation exposure associated
with radionucleotide imaging. In fact, some authors recom-
mend direct invasive coronary angiography for those with
high calcium scores (>400) despite atypical symptoms and a
lack of any testing suggesting ischemia [33]. An additional
consideration that favors coronary CTA as the preferred CT-
based test for symptomatic patients, in addition to the im-
proved prognostic performance and lack of significant test
layering [59], is the fact that the average radiation exposure
for patients undergoing coronary CTA in most experienced
centers is <5 mSv and is often comparable to the effective
radiation dose seen in CAC scanning.
Though several peer-reviewed cost comparisons exist for
current noninvasive modalities [59–67], similar data com-
paring CAC to the usual care of symptomatic patients is
limited. While recent NICE guidelines provide an interest-
ing assessment of potential cost savings of a ‘CAC first’
strategy in low-risk symptomatic patients, it should be cau-
tioned that this cost analysis was primarily aimed toward
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Fig. 2 Receiver-operator characteristic curves: major adverse events.
Receiver-operator characteristic curves of four models for predicting
composite major adverse events in 8907 patients within the CONFIRM
registry over a median of 2.1 years of follow-up. Model 2 (Morise
score+CAC score) was superior to model 1 (symptoms and risk factors
alone by Morise score), p<0.001. Model 3 (Morise score+number of
vessels with ≥50% stenosis on CTA) was superior to model 2 (risk
factors+CAC score), p<0.001, demonstrating superiority of CTA
versus CAC for risk prediction. In addition, when CTA was added to
CAC scores, event prediction was improved: Model 4 (Morise score+
CAC score+number of vessels ≥50% stenosis on CTA) superior to
Model 2, p<0.001. There was no additional value by adding CAC to
models with CTA stenosis: Model 4 not superior to model 3 (p=0.84).
AUC, area under the receiver-operator curve; CAC, coronary artery
calcification; CI, confidence interval; SE, standard error. *Adapted
with permission from Villines TC, et al. [34••]
Fig. 3 Major adverse events
stratified by presence of
coronary artery calcification
and stenosis on coronary ct
angiography from the confirm




infarction; Pos, positive for
CAC (CAC>0); Revasc,
revascularization occurring >90
days following coronary CTA.
*Adapted with permission from
Villines TC, et al. [34••]
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patients with stable chest pain and, thus, should not be
extended to patients with acute symptoms, a touted setting
for CAC application [2••]. Citing expert opinion, the NICE
cost analysis assumed a sensitivity for CTA of 80% for the
detection of stenosis of at least 70%, which is lower than the
sensitivites included for both SPECT (86%) and CAC only
(89%). This assumption ignores significant literature,
including several multi-center studies of the accuracy of
coronary CTA, reporting coronary CTA as the most sensi-
tive non-invasive test for ruling out significant CAD [10].
Among patients with acute symptoms in whom CAC
testing has been potentially advocated for use, we recognize
that CAC testing is attractive based on its relatively low
cost, reproducibility, ease of performance and interpreta-
tion, and potential use after business hours when other
modalities requiring more logistical support such as stress
echocardiogram, SPECT and coronary CTA may be
unavailable. However, it is important to note that the
binary use of CAC scanning in symptomatic patients has
not been rigorously validated in a large, prospective, mul-
ticenter manner. Conversely, coronary CTA has been re-
cently shown in several recent prospective, multi-center
trials to be safe, accurate and cost-efficient when
performed early for patients with acute chest pain; making
it, in our opinion, the preferred testing strategy for patients
with acute symptoms not at high pre-test risk who are felt
to require further testing [12].
Conclusions
Coronary artery calcium testing in asymptomatic patients
has been shown to significantly improve cardiovascular risk
prediction beyond that provided by standard cardiovascular
risk variables. Among symptomatic patients, CAC testing
has generally high sensitivity and NPV for excluding sig-
nificant CAD and subsequent adverse cardiovascular events
when performed in low-intermediate risk patients. However,
the widespread clinical application of CAC testing in symp-
tomatic patients may be significantly limited by the high
prevalence of coronary calcification in the population and
low specificity of CAC for obstructive CAD, requiring high
rates of additional testing to exclude significant CAD in
most symptomatic populations as compared to the use of
other standard non-invasive tests. In light of its potential
diagnostic inefficiency and the absence of large-scale, pro-
spective studies demonstrating the accuracy, safety and cost-
effectiveness of a ‘CAC-first’ approach, and recognizing the
progressively lower radiation doses and comparably favor-
able prognostic information obtained using modern coro-
nary CTA, we feel that coronary CTA is the preferred CT-
based test for symptomatic patients.
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